This chapter reviews how improvements in sensitivity and specificity of thyroid function tests [total and free thyroid hormones, TSH, thyroid autoantibodies (TRAb, TPOAb and TgAb) and …
B Gorovits, A Clements-Egan, M Birchler, M Liang… - The AAPS journal, 2016 - Springer
Pre-existing antibodies to biotherapeutic drugs have been detected in drug-naïve subjects for a variety of biotherapeutic modalities. Pre-existing antibodies are immunoglobulins that …
L Amaravadi, A Song, H Myler, T Thway, S Kirshner… - Bioanalysis, 2015 - Taylor & Francis
The 2015 9th Workshop on Recent Issues in Bioanalysis (9th WRIB) took place in Miami, Florida with participation of 600 professionals from pharmaceutical and biopharmaceutical …
V Väisänen, MT Peltola, H Lilja, M Nurmi… - Analytical …, 2006 - ACS Publications
Various blood constituents can interfere with immunoassays, usually by binding the Fc portion of antibodies. Our previously developed assays for intact free prostate-specific …
JE Gehin, RA Klaasen, ES Norli, DJ Warren… - Rheumatology …, 2021 - Springer
The aim of the study was to assess RF cross-reactivity to animal antibodies used in immunoassays, and to test if selected commercial immunoassays are vulnerable to …
N Bolstad, DJ Warren, J Bjerner, G Kravdal… - Clinical Chemistry and …, 2011 - degruyter.com
Background: Heterophilic antibodies are still an important source of interference in immunoassays. We have conducted a screening study for interference in a panel of …
The development of biotechnology-based active pharmaceutical ingredients, such as GLP-1 analogs, brought changes in type 2 diabetes treatment options. For better therapeutic …
JLE Campbell, JE Omakor - US Patent 8,084,272, 2011 - Google Patents
The invention is directed to methods and devices for reducing interference from heterophile antibodies in an analyte immunoassay. In one embodiment, the invention is to a method …
J Visentin, L Couzi, C Dromer, M Neau-Cransac… - Biosensors and …, 2018 - Elsevier
Human leukocyte antigen (HLA) donor-specific antibodies are key serum biomarkers for assessing the outcome of transplanted patients. Measuring their active concentration, ie the …